SPECIAL SECTION: MONOCLONAL ANTIBODIES
WHERE TO GET IN VITRO MABs: ACADEMIC CORE CENTERS AND COMMERCIAL FACILITIES
The amount of MAB needed varies with the intended use. Most research projects and many analytic purposes require only small amounts of a MAB (< 0.1 g). Larger quantities are necessary for routine diagnostic procedures and for therapeutic purposes. Commercial biotechnology companies now handle most of the large-scale production, typically using in vitro methods. Small-scale production in individual research labs accounts for most use of the ascites method these days.
Core centers, located at academic institutions, offer a good alternative for researchers needing small MAB amounts. These are not-for-profit, centralized facilities that offer specialized laboratory services to investigators on a fee-for-service basis. Many are at least partially funded by the National Institutes of Health. Using a core laboratory can provide a more cost-effective way for many investigators to use MABs produced by in vitro methods.
The listings below provide contact information for suppliers of in vitro monoclonal antibodies, including both commercial companies and core laboratories. There may be some overlap among the various lists.
ARDF Resource List of In Vitro MAB Producers.
Johns Hopkins Genetic Resources Core Facility Cell Center
CAAT list of Core Facilities, with contact information.
Small-scale monoclonal antibody production in vitro: Methods and resources. L. Jackson, L. Trudel, and N. Lipman. In: Proceedings of the Production of Monoclonal Antibodies Workshop. Aug. 1999. Edited by J. E. McArdle and C J. Lund. Alternatives Research and Development Foundation.
University of California Center for Animal Alternatives (UCCAA) web site. MABs section: Companies and Core Facilities.
AWIC Information Resources for Adjuvant and Antibody Production: Comparisons and Alternative Technologies (1990-97): Companies and Institutes.
Antibody Resource Page
The Nature Biotechnology Directory
Core laboratories: What is their cost-effectiveness and what are their needs? Margaret Penno. In: CAAT Technical Report #8: Alternatives in Monoclonal Antibody Production. Sept. 1997.